Literature DB >> 30819588

PEDF increases GLUT4-mediated glucose uptake in rat ischemic myocardium via PI3K/AKT pathway in a PEDFR-dependent manner.

Yanliang Yuan1, Xiucheng Liu1, Haoran Miao1, Bing Huang1, Zhiwei Liu2, Jiali Chen1, Xiaoyu Quan1, Lidong Zhu1, Hongyan Dong3, Zhongming Zhang4.   

Abstract

BACKGROUND: Targeted increase in glucose uptake of ischemic myocardium is a potential therapeutic strategy for myocardial ischemia. PEDF presents a profound moderating effect on glucose metabolism of cells, but its role is still controversial. Here, we try to demonstrate the direct effect of PEDF on glucose uptake in ischemic myocyte and to elucidate its underlying mechanism. METHODS AND
RESULTS: Lentivirus vectors carrying PEDF gene were delivered into the myocardium to locally overexpress PEDF in a myocardial ischemia/reperfusion rat model. PET imaging showed that PEDF local overexpression increased [18F]-FDG uptake of ischemic myocardium. In vitro, PEDF directly increased the glucose uptake in hypoxic cardiomyocytes. The expression of glucose transporter 4 (GLUT4) on plasma membrane of hypoxic cardiomyocytes was significantly upregulated by PEDF, but its total amount was not changed. The increased glucose uptake and cardioprotective effects induced by PEDF were blocked by the GLUT4 inhibitor indinavir. PEDF-mediated GLUT4 translocation and glucose uptake increase in hypoxic cardiomyocytes were prevented by phosphatidyl-inositol-3 kinase (PI3K) inhibitor or AKT inhibitor. The PEDF-mediated glucose uptake was also diminished when PEDF receptor (PEDFR) was downregulated or potent phospholipase A2 enzymatic activity was inhibited.
CONCLUSIONS: PEDF can increase glucose uptake in ischemic myocardium through a PEDFR-dependent mechanism, involving PI3K/AKT signaling and GLUT4 translocation.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Acute myocardial infarction; Glucose transporter 4; Glucose uptake; Phosphatidyl-inositol-3 kinase/AKT pathway; Pigment epithelium derived factor

Year:  2019        PMID: 30819588     DOI: 10.1016/j.ijcard.2019.02.035

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  Current understanding of glucose transporter 4 expression and functional mechanisms.

Authors:  Tiannan Wang; Jing Wang; Xinge Hu; Xian-Ju Huang; Guo-Xun Chen
Journal:  World J Biol Chem       Date:  2020-11-27

2.  DRD4 Mitigates Myocardial Ischemia/Reperfusion Injury in Association With PI3K/AKT Mediated Glucose Metabolism.

Authors:  Xue-Song Liu; Jing Zeng; Yu-Xue Yang; Chun-Lei Qi; Ting Xiong; Geng-Ze Wu; Chun-Yu Zeng; Da-Xin Wang
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

3.  Upregulation of PEDF Predicts a Poor Prognosis and Promotes Esophageal Squamous Cell Carcinoma Progression by Modulating the MAPK/ERK Signaling Pathway.

Authors:  Zui Chen; Di Che; Xiaoqiong Gu; Jiamin Lin; Jing Deng; Ping Jiang; Kaixiong Xu; Banglao Xu; Ting Zhang
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

4.  Lung but not brain cancer cell malignancy inhibited by commonly used anesthetic propofol during surgery: Implication of reducing cancer recurrence risk.

Authors:  Cong Hu; Masae Iwasaki; Zhigang Liu; Bincheng Wang; Xiaomeng Li; Han Lin; Jun Li; Jia V Li; Qingquan Lian; Daqing Ma
Journal:  J Adv Res       Date:  2021-01-06       Impact factor: 10.479

5.  OM-MSCs Alleviate the Golgi Apparatus Stress Response following Cerebral Ischemia/Reperfusion Injury via the PEDF-PI3K/Akt/mTOR Signaling Pathway.

Authors:  Jialin He; Jianyang Liu; Yan Huang; Xiangqi Tang; Han Xiao; Zuo Liu; Zheng Jiang; Liuwang Zeng; Zhiping Hu; Ming Lu
Journal:  Oxid Med Cell Longev       Date:  2021-11-13       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.